Agilent Technologies Inc (NYSE:A) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its position in shares of Agilent Technologies Inc (NYSE:A) by 14.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 249,851 shares of the medical research company’s stock after selling 43,255 shares during the period. Robeco Institutional Asset Management B.V. owned 0.08% of Agilent Technologies worth $18,656,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in shares of Agilent Technologies by 4.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,031,349 shares of the medical research company’s stock worth $69,567,000 after buying an additional 47,062 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Agilent Technologies by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,234,035 shares of the medical research company’s stock worth $285,139,000 after purchasing an additional 285,330 shares in the last quarter. First Allied Advisory Services Inc. raised its holdings in shares of Agilent Technologies by 7.6% in the 4th quarter. First Allied Advisory Services Inc. now owns 4,153 shares of the medical research company’s stock worth $282,000 after purchasing an additional 295 shares in the last quarter. Chesley Taft & Associates LLC raised its holdings in shares of Agilent Technologies by 75.0% in the 1st quarter. Chesley Taft & Associates LLC now owns 21,669 shares of the medical research company’s stock worth $1,742,000 after purchasing an additional 9,289 shares in the last quarter. Finally, Pacer Advisors Inc. bought a new stake in shares of Agilent Technologies in the 1st quarter worth approximately $2,275,000.

A traded down $1.13 on Friday, reaching $68.08. 2,803,508 shares of the company traded hands, compared to its average volume of 2,869,115. The business has a 50 day moving average price of $71.82. Agilent Technologies Inc has a 52-week low of $61.01 and a 52-week high of $82.27. The stock has a market cap of $21.87 billion, a P/E ratio of 24.40, a price-to-earnings-growth ratio of 1.93 and a beta of 1.41. The company has a current ratio of 3.41, a quick ratio of 2.82 and a debt-to-equity ratio of 0.35.

Agilent Technologies (NYSE:A) last posted its earnings results on Tuesday, May 14th. The medical research company reported $0.71 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.01). The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.27 billion. Agilent Technologies had a return on equity of 19.71% and a net margin of 22.25%. The business’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.65 earnings per share. On average, sell-side analysts anticipate that Agilent Technologies Inc will post 3.05 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd were paid a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend was Monday, July 1st. Agilent Technologies’s payout ratio is 23.66%.

A has been the topic of a number of research reports. Deutsche Bank dropped their target price on shares of Agilent Technologies from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 15th. Zacks Investment Research lowered shares of Agilent Technologies from a “hold” rating to a “sell” rating and set a $71.00 price target on the stock. in a report on Tuesday, July 16th. ValuEngine lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Friday, July 12th. Piper Jaffray Companies assumed coverage on shares of Agilent Technologies in a report on Tuesday, June 11th. They set an “overweight” rating and a $83.00 price target on the stock. Finally, Barclays lowered shares of Agilent Technologies from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $86.00 to $78.00 in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $83.92.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: Stock Symbols and CUSIP Explained

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.